Roy Guinto, D.O.
Endocrinology, Diabetes & Metabolism Physician in Wexford, Pennsylvania. This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 7,852 in Endocrinology, Diabetes & Metabolism Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Roy Guinto, D.O. reported a CMS MIPS final score of 77.5/100 - below the 83.1 national average - and filed 1,348 Medicare Part D claims in 2023.
- 77.5/100
- MIPS score · -6 vs avg
- 1K
- Part D claims, 2023
- 40%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Roy Guinto, D.O.'s MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure
78 24th percentile higher than 24% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Roy Guinto, D.O. sits
This provider among endocrinology, diabetes & metabolism physician peers
Across the 2,521 endocrinology, diabetes & metabolism physician providers who report both Medicare Part D prescribing and a MIPS quality score, Roy Guinto, D.O. writes more Part D claims than 32% of them and scores higher on MIPS quality than 27% - placing this provider in the lower-volume, lower-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Part D claim volume vs MIPS quality, by specialty percentile
Each dot is one endocrinology, diabetes & metabolism physician peer from a representative sample of 60; the gold marker is Roy Guinto, D.O.. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
Roy Guinto, D.O. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Roy Guinto, D.O.?
Below national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Pennsylvania
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among Pennsylvania providers
Largest specialties in Pennsylvania (% of in-state providers)
Endocrinology, Diabetes & Metabolism Physician ranks #82 among Pennsylvania's specialties (0.1% of in-state providers)
Each bar is a specialty's share of the Pennsylvania provider total, by primary NUCC taxonomy. The highlighted bar is Endocrinology, Diabetes & Metabolism Physician; the long tail of smaller specialties is omitted for legibility.
Medicare quality performance, MIPS
Roy Guinto, D.O.'s 2023 MIPS final score plotted against the Endocrinology, Diabetes & Metabolism Physician national average
- MIPS Final Score
- 77.5/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Endocrinology, Diabetes & Metabolism Physician) - 77.5/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Cost dim CMS Cost category
- Specialty volume Endocrinology, Diabetes & Metabolism Physician US NPIs
77.5/100 MIPS final score - 5.6 pts below the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Endocrinology, Diabetes & Metabolism Physician. Quality dim: 68.6. Cost dim: 56.4.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Roy Guinto, D.O. appears in the CMS NPPES registry as a Endocrinology, Diabetes & Metabolism Physician provider holding D.O. credentials at 117 VIP DR STE 120, Wexford, PA, 15090, with a listed phone of (412) 586-9700. NPI 1427378884 was issued on 06/09/2010. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what Guinto most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 1,348 prescription claims written by this provider, covering 208 Medicare beneficiaries and totaling roughly $679K in drug spend, split 52% brand-name and 40% generic by claim count. These figures capture only Medicare Part D, commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 77.5/100 for the 2023 performance year (Quality 68.6, Cost 56.4), compared with the national average of 83.1.
Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,852 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1427378884 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Credentials | D.O. |
| Gender | Male |
| NPI Issued | 06/09/2010 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm Roy Guinto, D.O.'s current license status, disciplinary history, and board certifications with the Pennsylvania State Board of Medicine in Pennsylvania before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
Hospital and facility affiliations
Facilities where Roy Guinto, D.O. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Roy Guinto, D.O.. Source: openpaymentsdata.cms.gov.
Total received
$341
Largest payer
Amgen Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - Pennsylvania PA-BOM 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~45K Pennsylvania medical licensees in 2023 - they are NOT specific to Roy Guinto, D.O.. To verify Roy Guinto, D.O.'s current license status, search the PA-BOM public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
PA-BOM publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Pennsylvania disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Brand-heavy
52% brand-name claims vs 40% generic, on 1,348 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 2,852
- Total Day Supply
- 83,684
- Brand vs Generic
- 52% brand / 40% generic
- Brand Drug Cost
- $646K
- Generic Drug Cost
- $19K
Patient Demographics
- Average Patient Age
- 68.7 years
- Avg HCC Risk Score
- 1.59
- Gender Split
- 58% female / 42% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Roy Guinto, D.O. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Levothyroxine Sodium
Levothyroxine Sodium
131 claims
- Ozempic
Ozempic
100 claims
- Metformin Hcl Er
Metformin Hcl Er
97 claims
- Trulicity
Trulicity
93 claims
- Jardiance
Jardiance
56 claims
- Humalog Kwikpen U-… 49
Humalog Kwikpen U-100
49 claims
- Alendronate Sodium 42
Alendronate Sodium
42 claims
- Synthroid 33
Synthroid
33 claims
| Drug | Claims |
|---|---|
| Levothyroxine Sodium | 131 |
| Ozempic Semaglutide | 100 |
| Metformin Hcl Er Metformin Hcl | 97 |
| Trulicity Dulaglutide | 93 |
| Jardiance Empagliflozin | 56 |
| Humalog Kwikpen U-100 Insulin Lispro | 49 |
| Alendronate Sodium | 42 |
| Synthroid Levothyroxine Sodium | 33 |
| Mounjaro Tirzepatide | 30 |
| Novolog Flexpen Insulin Aspart | 25 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Endocrinology, Diabetes & Metabolism Physician Overview
How Roy Guinto, D.O. fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
Roy Guinto, D.O.'s 1,348 claims are below the specialty average of 2,639.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in Pennsylvania
Other clinicians with the same primary specialty enrolled in Pennsylvania, drawn from the same CMS NPPES roster as Guinto.
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the Pennsylvania medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Endocrinology, Diabetes & Metabolism Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Pennsylvania
Frequently Asked Questions
What is Roy Guinto, D.O.'s specialty? ▼
How much does Roy Guinto, D.O. prescribe under Medicare Part D? ▼
What is Roy Guinto, D.O.'s Medicare quality score? ▼
Where is Roy Guinto, D.O. located? ▼
What is Roy Guinto, D.O.'s NPI number? ▼
Does Roy Guinto, D.O. prescribe more brand-name or generic drugs? ▼
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
What drugs does Roy Guinto, D.O. prescribe most often? ▼
Does Roy Guinto, D.O. accept Medicare? ▼
How can I verify Roy Guinto, D.O.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology